SAB BIOTHERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
SAB BIOTHERAPEUTICS, INC. (SABS) reported Increase (Decrease) in Accrued Liabilities of $251.15 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-22.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2021-11-22
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2021-09-30 was $169.50K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2021-06-30 was $72.88K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2021-03-31 was $8.78K.
| Period end | Increase (Decrease) in Accrued Liabilities 2 month | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month |
|---|---|---|---|---|
| 2021-09-30 | $169.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-22 | $242.38K derived: sum of 2 quarters · filed 2021-11-22 | $251.15K 10-Q · filed 2021-11-22 | |
| 2021-06-30 | $72.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $81.66K 10-Q · filed 2021-08-09 | ||
| 2021-03-31 | $8.78K 10-Q · filed 2021-05-21 | |||
| 2020-12-31 | $1.22K 10-K · filed 2021-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |